■ The use of prescription stimulants to enhance healthy cognition has significant social, ethical, and public health implications. The large number of enhancement users across various ages and occupations emphasizes the importance of examining these drugs' efficacy in a nonclinical sample. The present meta-analysis was conducted to estimate the magnitude of the effects of methylphenidate and amphetamine on cognitive functions central to academic and occupational functioning, including inhibitory control, working memory, short-term episodic memory, and delayed episodic memory. In addition, we examined the evidence for publication bias. Forty-eight studies (total of 1,409 participants) were included in the analyses. We found evidence for small but significant stimulant enhancement effects on inhibitory control and short-term episodic memory. Small effects on working memory reached significance, based on one of our two analytical approaches. Effects on delayed episodic memory were medium in size. However, because the effects on long-term and working memory were qualified by evidence for publication bias, we conclude that the effect of amphetamine and methylphenidate on the examined facets of healthy cognition is probably modest overall. In some situations, a small advantage may be valuable, although it is also possible that healthy users resort to stimulants to enhance their energy and motivation more than their cognition. ■
INTRODUCTION
The scientific and popular literatures both document the use of prescription medications by healthy young people to enhance cognitive performance in school and on the job (e.g., Smith & Farah, 2011; Talbot, 2009 ). This practice, called "cognitive enhancement," has provoked wide discussion of its potential social, ethical, and public health consequences (Greely, 2013; Sahakian & MoreinZamir, 2011; Farah et al., 2004) . Recently, another question concerning cognitive enhancement has arisen: To what degree do the medications used for cognitive enhancement in fact improve the abilities of cognitively normal individuals?
In view of the prevalence of cognitive enhancement and the intensity of academic and policy interest in this practice, it is surprising that the answer to this question has not been clearly established. The empirical literature on the effects of these stimulants on cognition in normal participants has yielded variable results, with some reviewers doubting their efficacy altogether. For example, in reviewing the literature on the cognitive effects of methylphenidate, Repantis, Schlattmann, Laisney, and Heuser (2010) concluded that they were "not able to provide sufficient evidence of positive effects in healthy individuals from objective tests." Hall and Lucke (2010) stated: "There is very weak evidence that putatively neuroenhancing pharmaceuticals in fact enhance cognitive function." Advokat (2010) concluded her review of the literature by stating that "studies in non-ADHD adults suggest that stimulants may actually impair performance on tasks that require adaptation, flexibility and planning." Smith and Farah (2011) attempted to test the hypothesis that stimulants enhance cognitive performance in normal healthy participants with a systematic literature review. We included studies of amphetamine and methylphenidate's effects on episodic and procedural memory and three categories of executive function: working memory, inhibitory control, and third category of other executive function tasks that did not fit into either of the first two. Results were mixed, with large effects, small effects, and null effects all reported. For example, over a third of the executive function studies reported null results. One interpretation of this pattern is that the drugs confer a small benefit, which may fail to be detected in some studies because of inadequate power. The other possibility is that chance positive findings, combined with publication bias, may be responsible for the positive evidence that exists in the literature. Thus, despite the large literature included in our review, we were forced to conclude that "there remains great uncertainty regarding the size and robustness of these effects." Meta-analysis is a method that can distinguish between the competing interpretations of the findings in the cognitive enhancement literature.
The primary goal of the present meta-analysis is to obtain a quantitative estimate of the cognitive effects of the stimulants amphetamine and methylphenidate. They are commonly prescribed for the treatment of attention deficit hyperactivity disorder (ADHD) but are frequently diverted for enhancement use by students and others (e.g., Wilens et al., 2008; Poulin, 2007; McCabe, Teter, & Boyd, 2006) . Guided by the findings of Smith and Farah's (2011) review, we focus on the cognitive processes that seemed most likely to be enhanced by stimulants, specifically inhibitory control, working memory, and episodic memory. In addition, because this earlier review found the strongest evidence of episodic memory enhancement after long delays between learning and test, we distinguish between episodic memory tested soon after learning (within 30 min after learning trials) and episodic memory tested after longer intervals (1 hr to 1 week).
The meta-analysis has two additional goals: one is to test hypotheses about moderators of the effects, that is, differences between studies that might account for the variability in effectiveness noted across different studies. For example, perhaps one of the stimulants is effective and the other less so, or perhaps low doses are more effective than higher doses. The final goal is to assess the role of publication bias in shaping the literature and potentially inflating effect size estimates. This would happen if, as hypothesized (e.g., Smith & Farah, 2011) , underpowered studies obtained large statistically significant effects by chance and thereby entered the literature while the balancing effects of smaller or null results from similar studies remained unpublished.
METHODS Search Strategies
Online databases PubMed and PsychInfo were searched with key words amphetamine and methylphenidate, each combined with each of the following: executive function, executive control, cognitive control, inhibitory control, inhibition, working memory, flanker, stop signal task, stop task, no-go, card-sort, ID/ED, set shifting, Sternberg memory, Stroop, Digit Span, memory, learning, recall, recognition, and retention. These searches were narrowed to exclude research on nonhuman participants, qualitative studies, and nonempirical publications (e.g., review articles, meta-analyses, lectures, news articles, etc.). In addition, the reference sections of the following review articles were searched for relevant articles: Chamberlain et al. (2011) , Smith and Farah (2011) , Advokat (2010) , and Repantis et al. (2010) . Finally, we searched the list of articles being reviewed by an American Academy of Neurology committee studying cognitive enhancement on which the last author serves. All research published through the end of December 2012 were eligible.
We also sought relevant unpublished data to include in the meta-analyses. Twenty researchers active in the area were contacted for unpublished data on amphetamine or methylphenidate effects on episodic memory, working memory, or inhibitory control in healthy nonelderly adults. In addition, 14 requests were made for additional data from studies published in the past 10 years but reporting insufficient data to calculate effect sizes. This led to obtaining two data sets of studies in progress or in submission as well as additional effect size data from four published reports. An additional unpublished pilot data set from our laboratory was also included.
Criteria for Study Eligibility

Publication Type and Language
Empirical investigations in any report format were eligible for inclusion in the meta-analysis. These included journal articles as well as dissertations, conference presentations, and unpublished data sets. The latter three were considered in an attempt to minimize the influence of publication bias on the obtained effect size estimates. Only reports in English were included.
Eligible interventions were orally administered amphetamine and methylphenidate, with drugs administered before the start of the cognitive protocol (e.g., not after learning in a memory experiment). We only included research on single-dose administration (the only study on the effect of repeated administration was excluded because of lack of consistency of intervention strength with the rest of the available research). In the included studies, the interval between drug administration and the cognitive task ranged between 30 min and 4.5 hr for amphetamine studies and 40 min and 4.5 hr for research on methylphenidate. These intervals are within the medications' window of effectiveness (Volkow et al., 1998; Angrist, Corwin, Bartlik, & Cooper, 1987; Vree & Van Rossum, 1970) . In addition, it is not unreasonable to suspect that these waiting times have ecological validity, with users working or studying similar intervals after drug intake.
Studies including multiple intervention arms, such as different drugs or TMS, were included only if the effects of amphetamine and methylphenidate could be assessed in isolation (e.g., without concurrent TMS) and compared with placebo.
Cognitive Systems under Investigation
Four abilities central to academic and professional work were included based on the findings of Smith and Farah's (2011) literature review. They were inhibitory control, the ability to override dominant, habitual, or automatic responses for the sake of implementing more adaptive, goal-directed behaviors; working memory, the capacity to temporarily store and manipulate information in the service of other ongoing cognitive functions; episodic memory, the ability to encode, store, and retrieve taskrelevant information, assessed shortly after learning (i.e., within 30 min) and at longer delays (1 hr to 1 week). Whenever task descriptions were not sufficient to identify the cognitive function tested, the data were excluded.
Outcome Measures
Performance can be measured by RT, overall accuracy, or specific types of error such as misses or false alarms. Overall in the literature, research reports varied in the types and number of outcome measures reported for each task. To maintain the validity and consistency of outcome measures in our analyses, we designed an a priori outcome selection procedure, as shown in Table 1 . Our outcome selection strategy favored the most widely used and construct valid measures but also included second-best options, whenever our first choices were not reported. In general, we favored error measures over RT measures unless accuracy was near ceiling; in which case, RT data, if available, were coded. On tests of inhibitory control, instead of overall accuracy, more specific accuracy measures (or the relationships thereof ) were used, such as a measure of false alarms on go/no-go tasks or the contrast in performance on incongruent and congruent trials of Flanker and Stroop. Whenever relevant, our main outcome measure was tailored to the specific design of the task. Particularly, two variants of the stop signal task of inhibitory control have been used in the examined literature: a version where the probability of stopping is allowed to vary and is the main measure of inhibition (e.g., Fillmore, Kelly, & Martin, 2005) and a version where the probability of stopping is held constant (e.g., De Wit, Enggasser, & Richards, 2002; Logan, Schachar, & Tannock, 1997) , in which case stop signal RT is the main outcome. Eligible outcome measures for each task are shown in Table 1 .
Process of Determining Study Eligibility
The search process, summarized in Figure 1 , led to the identification of 1,799 titles, which were narrowed down to 1,505 after 294 duplicate articles were removed. After screening the titles of these articles, additional 1,304 reports were excluded for not meeting the inclusion criteria. The remaining 201 studies were assessed for eligibility by applying the exclusion criteria to the abstract and, in case of insufficient data, to the full text.
Of the remaining 201 studies, 73 were excluded because the measured cognitive constructs (e.g., simple RT, sustained attention, creativity, intelligence, fear conditioning, motor performance, reward processing, probabilistic learning, etc.) were outside the scope of the present review. Twelve studies failed to meet the criteria for eligible participants (mice: n = 1; elderly participants: n = 6; children: n = 2; mentally ill participants: n = 2, including one study on ADHD and one study on cocaine abuse; criminal participants: n = 1). Eighteen reports lacked a double-blind placebo-controlled design (when these design features were not explicitly mentioned, the study was excluded). Sixteen reports were excluded because of ineligible intervention. These included four studies that tested drugs other than amphetamine or methylphenidate, four studies in which drugs were administered intravenously, four studies conducted in the context of sleep deprivation, two studies in which outcomes were measured under TMS, one study in which drug administration followed (as opposed to preceding) learning, and one study that tested the effect of multiple drug doses. Seven studies in language other than English were excluded. Four studies could not be retrieved from available online and article sources. Four studies were excluded because of duplicating the data of already included research. In 19 of the remaining otherwise eligible studies, reported data were insufficient to calculate effect size. The final analyses were based on 48 articles reporting at least one relevant effect size (44 published reports, 3 unpublished data sets, and 1 dissertation with 1,409 participants). The first and second authors independently conducted the eligibility determination procedures; disagreements were resolved by consensus after reviewing the experimental reports.
Coding Procedures
All studies were coded by the first author, according to a standardized coding manual. Coded variables included means and standard deviations for performance under drug and placebo, sample size, outcome measure, effect direction, significance level, and several moderators. The moderators and rationale for examining their effects were that following:
(1) Drug (methylphenidate vs. amphetamine): This moderator analysis was conducted to examine if amphetamine and methylphenidate differ in their cognitive Cooper, et al. 2005) . In examining the role of dose in enhancement effects, we defined a "high" dose as amphetamine ≥ 20 mg and methylphenidate ≥ 40 mg. Doses below these benchmarks were coded as "low." (3) Caffeine restriction (present vs. absent): We explored the possibility that stimulants may be especially helpful in countering caffeine withdrawal, while possibly having limited effects on non-caffeine-withdrawn individuals.
The presence or absence of instructions to abstain from caffeinated beverages on the day of the experiment was coded as a possible moderator. (4) Gender distribution in the sample (percent male participants): In the past, higher rates of enhancement use have been reported among male students (e.g., Tèter, Mccabe, Cranford, Boyd, & Guthrie, 2005) , and differences in stimulants' subjective effects have been shown to vary as a function of gender and menstrual phase (White, Justice, & DeWit, 2002) . The percentage of men in the study sample was therefore tested as a moderator. (5) Risk of ceiling or floor effects (suspected vs. not):
Ceiling and floor effects could attenuate the estimated Only data from 2-and 3-back tasks were coded, excluding data from 0-back conditions (which capitalize on sustained attention more than working memory) and 1-back conditions (which, while taxing some working memory components, such as online maintenance, minimally tax other facets of working memory, such as monitoring and manipulation). Thus, we only included the n-back conditions that maximized the possibility of detecting drug effect and minimized the possibility of ceiling effects.
b When the data did not allow an inference about the presence or absence of ceiling or floor effects (i.e., the floor or the ceiling of the scale was not clearly defined or apparent), both accuracy and RT measures were coded. effect size. In these analyses, we examined whether the effect size in studies with no restriction of range differed from the effect size estimate in studies with suspected floor or ceiling effects. A study was coded as being at risk of range restriction if the larger among the means in the drug and placebo conditions was less than 1 SD away from the scale's floor or if the smaller mean was less than 1 SD away from the scale's ceiling. In case of moderation, our goal was to focus on the effect size estimate in the group of studies without suspected floor or ceiling effects. (6) Reason to publish if drug effects are null (present vs. absent): For the purpose of assessing publication bias for reports of behavioral effects of stimulants, we distinguished between effect sizes from studies that focused only on the effects of amphetamine or methylphenidate on healthy individuals and studies that also included clinical groups, other drugs, or nonbehavioral measures such as PET, fMRI, EEG, or ERP. We expected that smaller stimulant enhancement effects would be published in the context of studies addressing multiple questions (because of the higher likelihood of a positive finding given multiple measures and the greater resources invested in testing clinical populations, measuring neural activity, and administering multiple interventions). (7) For working memory tasks: Stimulus type (verbal vs.
visual vs. spatial) and type of working memory subprocess measured (maintenance vs. maintenance plus manipulation). Different stimuli types and working memory subprocesses are supported by different brain structures, raising a possibility for differential susceptibility to stimulant effects (e.g., Martinussen, Hayden, Hogg-Johnson, & Tannock, 2005; Wager & Smith, 2003) .
Effect sizes were calculated using means and standard deviations. Where these descriptives were not presented, we estimated them from published graphs. We favored descriptive over inferential statistics based on previous research showing that, in repeated-measures designs (most of the included studies), effect size estimates from descriptive statistics are less biased than those from repeated-measures inferential statistics (Dunlap, Cortina, Vaslow, & Burke, 1996) . In the absence of descriptive data, we estimated effect sizes from F (provided df = 1), t, and/ or p values. If effect sizes were directly reported, we estimated their confidence intervals for r equivalent (Rosenthal & Rubin, 2003) and converted the values to d. When data were unavailable from either reports or from graphs, they were requested from authors.
The second author independently coded a random sample of 44% of the means and standard deviations (including data, estimated from graphs) in the placebo and drug conditions. Analyses of reliability showed excellent agreement (two-way mixed-model intraclass correlation coefficient for absolute agreement > .99 in all cases).
Handling of Missing Data
Effect size data could not be retrieved or calculated from 19 reports. We performed all meta-analyses excluding all missing data. We did not impute data in missing cells because we had no reason to infer either zero or average sizes of these unreported effects (Cooper, 2010) . In other words, we had no sufficient data to ensure that these analyses would improve our effect size estimates, instead of introducing error.
Statistical Methods
Effect Size Metrics
Hedge's g was used as the primary effect size measure, whereby a value of .2 is conventionally considered small, .5 is considered medium, and .8 is considered large. Hedge's g is obtained by multiplying the effect size Cohen's d by a coefficient J, which corrects for the tendency for studies with small sample sizes to bias the mean effect size positively because of publication bias:
. In combining effect sizes, each was weighted by an estimate of its precision, that is, the inverse of the squared standard error of the effect size.
For within-subject designs, employed in most of the meta-analyzed articles, we have the option of calculating the effect size in two ways. Typically, for such designs, a measure of performance change is scaled by units of variability of change. This addresses the question, "How much drug-related benefit can one expect, relative to the variability of change scores in the sample?" Alternatively, the effect size can be expressed as the size of the drug treatment effect on performance, measured in units of performance variability, as in between-subject designs. Specifically, using this approach, the difference in performance attributable to the drug is measured against the standard deviation of the sample's placebo performance. In effect, this addresses the question, "how far along the distribution of normal performance does the drug push subjects?" This question is very appropriate to the study of cognitive enhancement when used to gain a competitive edge relative to an unmedicated population. In addition, some authors have argued that "subject differences are always of theoretical interest" because "they are present in the population to which we want to generalize," justifying the calculation of effect sizes from either within-or between-subject designs in units of variability (Cortina & Nouri, 2000, p. 49) . We report both types of effect size analysis here, placing primary emphasis on effect sizes measured relative to normal variability.
To conduct our primary analyses, we included research with both within-and between-subject designs and relied on effect sizes calculated as shown below. These formulas, typically used for between-subject designs, were modified so that the observed standard deviations in the placebo condition are entered in the analyses as values for both medication and placebo conditions. In particular:
In these analyses, t, F, and p values were used to derive effect sizes from between-subject designs, using the following formulas:
ð Þ q (after converting p and F to t).
Inferential statistics from within-subject designs were not included in these analyses because they inherently reflect drug effects relative to variability of change, rather than relative to performance variability.
Our secondary analyses focused on the change score (drug minus placebo), specifically the average benefit because of drug, relative to variability of change within the sample. Only within-subject designs contained information relevant to this question. To calculate Hedge's g for change in within-subject designs, the following formulas were used.
q . These formulas require the value of the correlation between repeated measures, which were not reported in the published studies. These values, necessary to adjust for the dependency between repeated measures in effect size calculations, were estimated based on similar data sets.
1,2
Handling of Studies with More than One Effect Size
One of the assumptions of meta-analysis is that each effect size comes from an independent sample. If this assumption is violated by the inclusion of more than one effect size per study, between-study variance will be underestimated, and the significance of the summary effect size will be overestimated. The following steps were taken to reduce the available data to a single effect size per study.
(1) When effect sizes for more than one construct per study were available, data on each construct (i.e., inhibition, working memory, and short-and long-term episodic memory) were separated in an individual meta-analysis. (2) When multiple doses of a drug were compared with placebo within the same study, effect size data from all doses were coded and averaged.
(3) When, in a given study, effect sizes were reported for more than one eligible task and/or measure per construct, a single average effect size estimate per construct was obtained. (4) When outcome data were available from various time intervals after the administration of the drug (e.g., when inhibitory control was tested 1, 2, and 3 hr after drug administration or when long-term episodic memory was measured at various retention intervals), the average effect size was entered in the main analyses.
Fixed vs. Random Effects Model
A fixed effects model assumes that the only source of effect size variability is sampling error. It therefore produces an effect size estimate that describes the analyzed studies but cannot be generalized to other trials. By contrast, in a random effects model, variability is assumed to arise from both sampling error and between-study variability. Effect sizes derived from this model can be generalized to research outside of the analyzed studies. For the present meta-analysis, we selected a random effects model because of the variability between individual studies in each meta-analysis (different drugs, doses, waiting times between drug administration and testing, measures of each specific cognitive function, individual differences between samples) and also because we wanted to generalize the findings beyond the examined research.
Estimation of Heterogeneity
Tests for heterogeneity determine whether the dispersion of the individual effect sizes around their mean value is greater than predicted solely on the basis of subject-level sampling error. One of the tests employed uses the Q statistic, which, if significant, rejects a null hypothesis of homogeneity. The second test, based on the I 2 statistic, generates an estimate of the between-study variance as a percentage of the total variance (between subjects plus subject level). Conventions for low, moderate, and high heterogeneity correspond to I 2 values of 25, 50, and 75, respectively (Lipsey & Wilson, 2001 ).
Moderator Analyses
Most commonly in the literature, moderator analyses are conducted only after a finding of significant heterogeneity. In contrast to this approach, we decided to conduct moderator analyses regardless of the results of the heterogeneity tests because a homogeneous set of findings may emerge either in the absence of moderators or in the presence of moderators whose effects cancel each other out.
We examined the effect of the dichotomous moderators described earlier using mixed effects analyses. This analytical model assumes that the effect size variation is due to a combination of systematic associations between moderators and effect sizes, random differences between studies, and subject-level sampling error. Finally, the moderating role of gender composition (measured as percent male) was examined through meta-regression, given the continuous nature of this moderator.
A feature of the data on some moderator variables demanded the following modification in some of the analyses. When analyzing the moderating role of dose, ceiling/ floor effects, working memory stimulus type, and working memory subprocess, there were several cases of more than one level of the moderating variable for per study (e.g., this occurred when more than one drug dose was administered per sample or when floor/ceiling effects were suspected for one outcome within a study but not for another). In these cases, we relied on two approaches to analysis. First, to satisfy the assumption of independence between effect sizes, we excluded studies that included data on more than one level of each moderator variable. In a second version of the analyses, we used the shifting-unit method of analysis (Cooper, 2010) . The shifting-unit method allows violation of the assumption of meta-analysis in which a study can contribute an effect size to each level of the moderator (e.g., high and low doses). The advantage of the first approach is that the analysis assumptions remain unviolated; the advantage of the second approach is that it makes use of maximum possible data points. The findings based on the two approaches were in agreement, so we only report data based on the second one.
Publication Bias
Publication bias refers to the greater tendency of studies with significant results to be published than nonsignificant findings. Publication bias can therefore bias the results of meta-analyses because the more significant findings typically have larger effect sizes than those remaining in file drawers (Lipsey & Wilson, 2001 ). To minimize bias in the current meta-analysis, we made efforts to locate and retrieve unpublished data (see Search Strategies above). In addition, we used three methods to assess the evidence for publication bias and the stability of the effect size estimates and to determine unbiased effect sizes: funnel plots, fail-safe N, and trim and fill (Lipsey & Wilson, 2001 ). These analyses were conducted without correcting effect sizes by the factor J, as described earlier. Only data from published reports were included in these analyses.
A funnel plot permits a qualitative test of publication bias by showing the effect sizes of the analyzed studies plotted against an estimate of those studies' precision (the inverse of standard error of the effect size in our graphs). Effect size estimates from more accurate studies (toward the top of the graph) should cluster closely around the true effect size, whereas effect sizes from less accurate studies should appear more broadly dispersed below. In the absence of publication bias, the more broadly dispersed effect size estimates should extend in a roughly symmetrical arrangement to either side of the more accurate estimates. A negative skew, where points in the lower left quadrant appear to be missing, is consistent with the operation of publication bias.
In cases of publication bias, the trim-and-fill procedure calculates an unbiased estimate of the effect size. In this procedure, the most extreme positive effects are removed ("trimmed") from analysis, and a mirror image of the trimmed effect sizes with the opposite direction is then imputed. Unbiased estimates of the overall effect size and its variance are calculated, respectively, from the trimmed and filled data.
The fail-safe N indicates the number of studies with a zero effect size that, if added to the analysis, would render the obtained mean effect size nonsignificant. The value of fail-safe N is considered large (and publication bias, an unlikely influence on the effect size estimate) if it exceeds 5k + 10, where k is the number of meta-analyzed studies (Rothstein, Sutton, & Borenstein, 2006) .
Tests for Outliers
The presence of outlier effect sizes was assessed through the sample-adjusted meta-analytic deviancy (SAMD) statistic. For each study, the value of this statistic represents the difference between this study's effect size and the point estimate of the effect size uninfluenced by this study, a difference weighed by the relevant variance terms (Huffcutt & Arthur, 1995 ). An effect size was considered an outlier if it met both of the following two criteria (Sockol, Epperson, & Barber, 2011) : First, in a scree plot of the distribution of absolute SAMD values, it deviates markedly from the slope (Huffcutt & Arthur, 1995) . Second, it falls in the top or bottom 2.5% of the SAMD distribution (which approximates a t distribution). This conservative, twopronged method for outlier detection was chosen because outliers could result from either error or true betweenstudy variation (Sockol et al., 2011) .
Software
The data were analyzed primarily using Comprehensive Meta-Analysis 2.0, with the exception of meta-regression analyses, completed in R 3.0.0.
RESULTS
Overview of Results
We report meta-analyses for the effects of stimulants on the four constructs of interest: inhibitory control, working memory, short-term episodic memory, and delayed episodic memory. Two sets of results are presented, corresponding to the two different ways of measuring effect sizes from within-subject designs described earlier. For each cognitive construct, we first present meta-analyses of within-and between-subject studies combined, measuring the size of the drug effect relative to variability in the normal population. We then present the effect sizes estimated in separate meta-analyses for within-subject and matched-group studies using the formula for withinsubject effect sizes described earlier. For the main analyses, we also report the results of moderator analyses and three measures related to publication bias. In reporting our secondary analyses, we do not detail the results of moderator and publication bias analyses, which, in all cases, were qualitatively similar to the results in our main analyses. Most effect sizes were small. Evidence of publication bias emerged in two cognitive domains. Characteristics of all effect sizes (outcomes, magnitude of effect, sample sizes, values of moderator variables) are presented in Tables 2-5 .
Stimulants' Effects on Healthy Inhibitory Control
Twenty-five studies (including two unpublished) reported sufficient data to calculate the size of stimulants' effect on inhibitory control. After examining the values of the SAMD statistic, no value fell within the top or bottom 2.5% of the distribution or notably deviated from the relatively flat line of the scree plot. Not all of these studies were suitable for each analysis, that is, a study whose effect size was derived from a repeated-measures t value was excluded from analyses relative to normal variability; and a between-subject study was excluded from analyses relative to variability of change. Data for calculating effect sizes relative to normal variability were available from 24 studies (see Table 2 ); effect size relative to variability of gain scores was also estimated from 24 studies.
Stimulants' mean effect on inhibitory control, when measured relative to normative variability of performance, was small but significantly different from zero: Hedge's g = 0.20, 95% CI [0.11, 0.30]. Effect size measured relative to the variability of gain scores was similarly small and significantly different from zero: Hedge's g = 0.19, 95% CI [0.11, 0.26] . No evidence for between-study heterogeneity emerged: Q(23) = 7.82, p > .99, I 2 = 0.00. Moderator analyses indicated that none of the candidate moderators impacted significantly the stimulant effects on cognition (all ps > .20).
A funnel plot based only on the published studies (N = 22) showed no evidence for publication bias: The distribution of studies was roughly symmetrical (Figure 2) . The trim-and-fill procedure led to the exclusion of no study, and the adjusted effect size estimates remained the same as reported above. However, the fail-safe N method indicated that 39 studies (less than two studies per each published report) with an effect size of zero would nullify the obtained results. Taken together, the lack of negative skew in the funnel plot and the robustness of the effect size estimate to trim-and-fill adjustment converge to suggest that the effect estimate obtained for inhibitory control is most likely not affected by publication bias. In other words, there is no evidence to suspect that the relatively modest number of studies needed to nullify the result has remained in file drawers.
Stimulants' Effects on Healthy Working Memory
Effect size data on stimulants' effects on working memory were available from 23 studies, three of which were unpublished. None of the effect sizes were outliers by our criteria. Relevant statistics for calculating effect size relative to normal variability were available from 20 studies (Table 3) . Effect size relative to variability of gain scores was calculated based on 23 studies with within-subject or matched-group designs.
Our main analyses indicated a near-significant small stimulant effect on working memory: Hedge's g = 0.13, 95% CI [−0.02, 0.27]. When measured relative to variability of the gain scores, the effect size was again estimated to be small but, this time, reached significance: g = 0.13, 95% CI [0.06, 0.20]. There was no significant evidence for heterogeneity: Q(19) = 7.74, p = .99, I 2 = 0.00. Moderator analyses were performed, but no evidence emerged for moderation by any of the examined variables.
The funnel plots, based on published studies only (Figure 3) , showed slightly negative skew. The trim-and-fill procedure trimmed 4 data points, reducing the abovereported effect size to a nonsignificant trend of d = 0.06, 95% CI [−0.08, 0.20]. Because the gain score effect size was significant, whereas the primary effect size was not, here, we also report the trim-and-fill results from our secondary analyses, where the effect size was again reduced to nonsignificant: d = 0.06, 95% CI [−0.03, 0.15], given a negatively skewed funnel plot. Taken together, the trimand-fill correction and the skew of the funnel plot suggest the presence of publication bias. Fail-safe N analyses were obviated by the lack of significance in the obtained effect size estimate.
Stimulants' Effects on Healthy People's Short-term Episodic Memory
Fourteen effect sizes (one unpublished) were considered for inclusion in the meta-analysis. Two SAMD values, equaling −8.53 (Burns, House, Fensch, & Miller, 1967) and 2.18 (Zeeuws, Deroost, & Soetens, 2010a) , exceeded the cutoff for exclusion and deviated markedly from the relatively flat line on the scree plot of absolute SAMD values. Therefore, these studies were excluded from further analyses after confirming correct data entry.
On the basis of 12 studies (see Table 4 ), the mean effect of stimulants on short-term episodic memory, relative to normal variation of performance, was small but significant: Hedge's g = 0.20, 95% CI [0.01, 0.38] . This was similar to the result observed when the effect size was measured relative to variability of gain scores (12 studies): Hedge's g = 0.22, 95% CI [0.09, 0.35] . No evidence for heterogeneity emerged in our main analyses: Q(11) = 4.44, p = .96, I 2 = 0.00. Moderator analyses indicated no significant influence of any of the examined moderators (all ps > .64). A funnel plot, based on the 11 published studies, showed slightly negative asymmetry ( Figure 4 ); yet, inconsistent with publication bias, the largest study had the largest effect. The trim-and-fill procedure trimmed three studies, reducing the effect size estimate to a nonsignificant d = 0.12, 95% CI [−0.06, 0.29] . The fail-safe N procedure showed that a mere two studies with an effect size of zero would be needed to nullify the obtained effect, casting doubt on this effect's robustness.
Stimulant Effects on Healthy People's Delayed Episodic Memory
Twelve effect sizes describing stimulants' effects on delayed episodic memory were reported. One outlier was excluded, given an SAMD value of 3.35 (Zeeuws et al., 2010a) , which fell in the top 2.5% of the distribution of SAMD scores.
On the basis of the remaining 11 effect sizes, estimated relative to normal variability (see Table 5 ), stimulants' mean effect on delayed episodic memory was significantly different from zero and medium in size: g = . 45, 95% CI [0.27, 0.63] . Similarly, analyses focusing on the mean gain, relative to the sample's variability of change, showed a medium-sized effect: Hedge's g = 0.44, 95% CI [0.26, 0.62]. There was no evidence for significant betweenstudy heterogeneity: I 2 = 0.00, Q(10) = 9.67, p = .47. We found a small but significant moderating effect of gender, Q(1) = 7.44, p < .01, β = 0.01, with larger drug effects for larger proportions of men in samples. In addition, there was a significant moderating effect of dose, Q(1) = 5.49, p = .02, indicating a larger effect for the smaller dose, Hedge's g = 0.64, 95% CI [0.40, 0.88], than the larger dose, Hedge's g = 0.20, 95% CI [−0.08, 0.48] . Note that these moderation effects are confounded with each other and with research group: All studies that used low doses of stimulants came from the same research group, tested only male participants, and tended to include memory tests at longer retention intervals (up to 1 week), whereas among tests of the high drug dose, the percentage of men in the sample ranged between 48% and 70% and retention intervals, with one exception, were 2 hr. No other factors were found to significantly moderate stimulants' effects (all ps > .52).
The funnel plot of these studies was negatively skewed, suggesting publication bias ( Figure 5 ). The trim-and-fill method trimmed five studies, reducing the estimated effect size to d = 0.26, 95% CI [0.04, 0.47]. According to the fail-safe N procedure, 59 studies were needed to nullify the significance level of the result. The negative skew of the funnel plot, combined with the trim-and-fill correction, suggests the presence of publication bias and indicates that the true effect size may be small. It is important to note, though, that inferences from the funnel plot are qualified by the presence of significant moderation (see Lau, Ioannidis, Terrin, Schmid, & Olkin, 2006) . In particular, the studies with the six largest effect sizes came from the same laboratory and tested the effect of a low stimulant dose on male-only samples, in part, over relatively longer retention intervals. Four of the five remaining studies with smaller effect sizes came from other research groups and examined the effects of a high stimulant dose on a mixed-gender sample over relatively shorter delays. Thus, the funnel plot might reflect true publication bias or might be driven by betweenstudy differences. If the latter is the case, the trim-andfill-adjusted effect size may be underestimating the true effect size (e.g., Peters, Sutton, Jones, Abrams, & Rushton, 2007) . Unfortunately, the proposed methods of unconfounding publication bias and moderating factors (e.g., conducting funnel plot analyses within a subgroup of studies) are applicable only to large meta-analyses (see Peters et al., 2010) .
DISCUSSION
Summary and Interpretation of Results
Earlier research has failed to distinguish whether stimulants' effects are small or whether they are nonexistent Smith & Farah, 2011) . The present findings supported generally small effects of amphetamine and methylphenidate on executive function and memory. Specifically, in a set of experiments limited to high-quality designs, we found significant enhancement of several cognitive abilities. We found a small but significant degree of enhancement of inhibitory control and short-term episodic memory. Effects on working memory were small and significant in one of our two analyses. Delayed episodic memory was unique in showing a medium-sized effect. However, both working memory and delayed episodic memory findings were qualified by possible publication bias.
Theoretically, the relatively more pronounced effects of delayed episodic memory, in comparison with shortterm episodic memory, suggest that stimulants may be affecting most potently memory consolidation in comparison with encoding or retrieval. This conclusion is consistent with previous proposals (e.g., Soetens, Hueting, Casaer, & D'Hooge, 1995; see also McGaugh & Roozendaal, 2009) but, again, qualified by the possibility of publication bias.
Several potentially important moderators were tested because of their scientific relevance for understanding the effects of stimulants on cognition and their practical relevance in determining whether stimulants might be more effective cognitive enhancers under some circumstances than others. Moderator analyses yielded only a few significant findings. Stimulant effects on delayed episodic memory were moderated by gender, with larger effects for samples with more men, and by dosage, with larger effects for smaller doses. Unfortunately, these two moderators were confounded in the studies analyzed and also confounded with research laboratory and retention interval, so we cannot draw firm conclusions about the effects of gender or dose.
Where no effects of moderators were found, this may be because of uncertainty or imprecision in moderator coding, for instance, the dichotomization of drug dose or the possibility of nonlinear relationships between drug effect and dose. Finally, partly for the sake of limiting the number of comparisons and partly because of limited availability of relevant information, we examined only a subset of all relevant moderators. For instance, we did not explore the moderating role of participant age, level of education, waiting time between drug administration and testing, length of testing session, or time of day. Moderators of great interest, which might be expected to affect results based on previous studies but which could not be assessed because of insufficient available data, include individuals' baseline cognitive ability and individuals' variants of dopamine-related genes such as COMT and DRD2 (see Hamidovic et al., 2009; Mattay et al., 2003 ; but see also Wardle, Hart, Palmer, & de Wit, 2013 , for null results). Consistent with the nonmonotonic relation between dopamine activity and performance, there is evidence that stimulants can impair performance in normal individuals who are especially high performing (Farah, Haimm, Sankoorikal, & Chatterjee, 2009; De Wit et al., 2002; De Wit, Crean, & Richards, 2000; Mattay et al., 2000) . It remains possible that some individuals who would not qualify for a diagnosis of ADHD could nevertheless benefit from stimulants to a greater degree than indicated by the present results and that some individuals could be impaired.
Could the effects documented here be driven by undiagnosed psychopathology in some participants? One might expect participants with ADHD or depression to perform better on stimulants and participants with anxiety disorders or bipolar disorder to be impaired by these drugs. Unfortunately, few publications included comprehensive, detailed description of procedure through which psychopathology was screened out, making it difficult to assess the quality of assessment. Nevertheless, all reports explicitly described their samples as "healthy" or "nonclinical." Thus, it is possible but unlikely that unrecognized mental illness is responsible for the pattern of obtained findings.
Neuroethical Implications
What do the results reported here imply for neuroethical issues surrounding the use of stimulants for enhancement? Should we be concerned about the fairness of students and workers competing with the help of stimulant drugs?
Is there a genuine benefit to be weighed against the risks of using these prescription drugs for enhancement? The overall small effects of stimulants on healthy people's inhibitory control and working and episodic memory might be taken to mean that these drugs would not deliver a practically significant performance advantage. If so, one might argue that neuroethical discussions are therefore moot at best (and encouraging of a false belief in the drugs' efficacy at worst, e.g., Hall & Lucke, 2010 ).
The present findings should temper these and other more skeptical assessments of stimulant medications for cognitive enhancement of healthy, cognitively normal individuals. Although the reported effects are smaller than these of some other cognitive enhancement techniques (e.g., mindfulness meditation, for which near-medium effects on inhibitory control have been documented; see Sedlmeier et al., 2012 , for a meta-analysis), the present findings show stimulant benefits comparable with the effects of other commonly used enhancement tools (e.g., physical exercise, the cognitive effects of which have been found to be similarly small; see Chang, Labban, Gapin, & Etnier, 2012 , for a meta-analysis). Furthermore, small effects can make a difference in academic and professional outcomes. Even on a single occasion, a small effect might make the difference between good and very good performance or between passing a school entrance or licensing examination or failing. It is also possible that these drugs may give a larger boost to cognitive functions not examined here (e.g., sustained attention, processing speed); to people not specifically studied in this meta-analysis (e.g., healthy participants with low cognitive performance or specific genotypes); or to performance under conditions not tested here, for example, fatigue, sleep deprivation, distraction, or repeated stimulant use (e.g., Breitenstein et al., 2006) . It is also possible that stimulants enhance cognitive performance in real-world contexts at least in part through effects on users' affective states. They have been found to alter users' emotions about, and interest in, tasks otherwise seen as boring and unrewarding Vrecko, 2013) .
The results of this meta-analysis cannot address the important issues of individual differences in stimulant effects or the role of motivational enhancement in helping perform academic or occupational tasks. However, they do confirm the reality of cognitive enhancing effects for normal healthy adults in general, while also indicating that these effects are modest in size.
